Literature DB >> 26783358

Impact of Combination Antibiogram and Related Education on Inpatient Fluoroquinolone Prescribing Patterns for Patients With Health Care-Associated Pneumonia.

Baoqi Liang1, James S Wheeler2, Lisa M Blanchette3.   

Abstract

BACKGROUND: Previous studies have shown that development of a unit-specific combination antibiogram improves optimal selection of empiric therapy for Gram-negative infections, yet no published data exist regarding the role of the combination antibiogram as an antimicrobial stewardship program tool for disease-specific prescribing.
OBJECTIVE: To evaluate the utility of a combination antibiogram to guide antibiotic prescribing for patients with health care-associated pneumonia (HCAP).
METHODS: This was a retrospective preprovider and postprovider education intervention study aimed to evaluate fluoroquinolone (FQ) use in patients with HCAP. Data were collected retrospectively to evaluate antibiotic prescribing patterns and patient outcomes.
RESULTS: A total of 87 patients were eligible for study inclusion. The primary end point, FQ days of therapy (DOT) was decreased by 2.3 days (P < 0.001). The secondary end point included FQ DOT per 1000 patient-days in patients with discharge diagnosis-related group of pneumonia and was decreased by 83.5 days (P = 0.08); double coverage reduced by 13% postintervention (P = 0.22); mean days of double coverage decreased by 2.1 days (P < 0.001), and length of stay was shortened by 2.1 days (P = 0.22). Clinical success was achieved more often in the postintervention group (90% vs 98%, P = 0.18) when compared with the preintervention group. No difference was found in microbiological outcomes in the subset of microbiologically evaluable patients (P = 0.57).
CONCLUSION: Facility-specific combination antibiograms may be used to inform antibiotic prescribing in HCAP patients.
© The Author(s) 2016.

Entities:  

Keywords:  antimicrobial stewardship; combination antibiogram; double coverage; fluoroquinolone; health care–associated pneumonia

Mesh:

Substances:

Year:  2016        PMID: 26783358     DOI: 10.1177/1060028015625658

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  5 in total

1.  Retrospective review of ceftriaxone versus levofloxacin for treatment of E. coli urinary tract infections.

Authors:  Samantha S Wang; Patrick D Ratliff; William R Judd
Journal:  Int J Clin Pharm       Date:  2017-11-17

2.  In Vitro Comparison of Ceftolozane-Tazobactam to Traditional Beta-Lactams and Ceftolozane-Tazobactam as an Alternative to Combination Antimicrobial Therapy for Pseudomonas aeruginosa.

Authors:  Kellie J Goodlet; David P Nicolau; Michael D Nailor
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

3.  What's New in Critical Illness and Injury Science? Identifying Sources of Nosocomial Infections to Improve Patient Outcomes in the Surgical Intensive Care Unit.

Authors:  Charles R Vasquez; Niels D Martin
Journal:  Int J Crit Illn Inj Sci       Date:  2019 Jan-Mar

4.  Moral and Contextual Dimensions of "Inappropriate" Antibiotic Prescribing in Secondary Care: A Three-Country Interview Study.

Authors:  Carolyn Tarrant; Eva M Krockow; W M I Dilini Nakkawita; Michele Bolscher; Andrew M Colman; Edmund Chattoe-Brown; Nelun Perera; Shaheen Mehtar; David R Jenkins
Journal:  Front Sociol       Date:  2020-02-20

Review 5.  The antibiogram: key considerations for its development and utilization.

Authors:  William R Truong; Levita Hidayat; Michael A Bolaris; Lee Nguyen; Jason Yamaki
Journal:  JAC Antimicrob Resist       Date:  2021-05-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.